Dr. Gerardo Andriulli, M.D. Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 2 Old County Rd, Barrington, RI 02806 Phone: 401-246-1195 Fax: 401-246-1985 |
Dr. Mindy S Rosenbloom, MD Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 26 Bosworth St Ste 5, Barrington, RI 02806 Phone: 401-289-0250 Fax: 401-289-0492 |
Dr. Diane E King, MD Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 464 Maple Avenue, Suite 2, Barrington, RI 02806 Phone: 401-247-0006 Fax: 401-247-0001 |
Catherine E Chase, DO Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 2 Old County Rd, Barrington, RI 02806 Phone: 401-246-1195 |
Dr. Randy Scott Freeman, D.O. Psychiatry & Neurology - Neurodevelopmental Disabilities Medicare: Medicare Enrolled Practice Location: 147 County Rd Ste 300c, Barrington, RI 02806 Phone: 401-285-6040 |
Richard Lambert, M.D. Psychiatry & Neurology - Psychiatry Medicare: Not Enrolled in Medicare Practice Location: 2 Old County Rd, Barrington, RI 02806 Phone: 401-246-1195 |
News Archive
Researchers report in Nature Communications they figured out why air sacs in the lungs clog up with a thick substance called surfactant in a brutal disease called Pulmonary Alveolar Proteinosis, and they show taking cholesterol-busting pills called statins can effectively treat the disease.
A recent look at what is known about the health effects of drinking water reveals that most supposed benefits are not backed by solid evidence.
The wider economic benefits of a tax on sugary drinks need to be recognised by policymakers if retailers' pricing behaviour is to be changed, according to a study led by the University of East Anglia.
The endoscopic approach worked well not only to remove large inverted papillomas in 18 patients ages 36 to 74 but also to watch for regrowth of the tumors that have a high recurrence rate and a small chance of becoming cancer. Patients were treated as outpatients and 56 percent remained disease-free at 29 months.
Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced the U.S. commercial availability of CUVPOSA™ (glycopyrrolate) oral solution, the first and only FDA-approved treatment to reduce chronic severe drooling in patients aged 3 to 16 with neurologic conditions associated with problem drooling, such as cerebral palsy.
› Verified 6 days ago